99mTc-Radiopharmaceutical
99mTc is a key isotope in nuclear medicine, widely used for diagnostic imaging in oncology, cardiology, and neurology due to its ideal properties. Alfa Cytology offers comprehensive 99mTc radiopharmaceutical development services, including molecular design, labeling optimization, preclinical testing, and custom tracer development for targeted diseases.
Overview of 99mTc-Based Radiopharmaceuticals
Technetium-99m (99mTc) is a cornerstone in nuclear medicine, renowned for its ideal physical properties—such as a 6-hour half-life, gamma emissions conducive to imaging, and high resolution with minimal radiation exposure. These features make 99mTc especially suitable for diagnostic radiopharmaceuticals targeting well-established areas such as tumor imaging (e.g., 99mTc-MIBI for cardiac and tumor imaging), bone metastases detection (99mTc-MDP), and lung perfusion studies.
Fig.1. 99mTc-Pyrophosphate-based SPECT combined with multislice CT angiography. (Ilyushenkova, J, et al., 2020)
Applications of 99mTc
99mTc is widely employed across multiple medical fields for diagnostic imaging, aiding in the detection, staging, and monitoring of various diseases. Its versatility allows for precise imaging in oncology, cardiology, neurology, and infectious diseases.
| Applications |
Description |
Related Agents |
| Oncology |
99mTc radiopharmaceuticals are vital in oncology for diagnosis, staging, and treatment monitoring. |
- 99mTc-MDP
- 99mTc-Sestamibi
- 99mTc-Tilmanocept
|
| Cardiology |
99mTc is extensively employed in the evaluation of myocardial perfusion and viability. |
- 99mTc-Sestamibi/Tetrofosmin
- 99mTc-Pyrophosphate
|
| Neurology |
99mTc-labeled tracers are utilized for cerebral blood flow studies and neuroreceptor imaging. |
- 99mTc-HMPAO/ECD
- 99mTc-TRODAT-1
|
| Infectious Diseases |
99mTc agents pinpoint infections and inflammation where traditional imaging falls short. |
- 99mTc-HMPAO-Leukocytes
- 99mTc-Ciprofloxacin
|
Our Services
We are committed to providing you with a one-stop 99mTc radiopharmaceutical development service that incorporates a model that provides the best possible radiopharmaceutical development solution at a level of efficiency and effectiveness.
Molecular Design & Development
- Tagging of different molecules using multiple labeling techniques that ensure yield, purity, and bioactivity.
- Development of high-affinity, in vitro stable 99mTc-labeled SPECT imaging agents for customized oncology, cardiology, and brain applications.
Labeling Optimization
- Use of cutting-edge approaches for labeling 99mTc with a wide range of molecules, ensuring high specificity and biological activity.
- Isolating and rigorously analyzing the labeled product's stability in vivo to ensure clinical relevance and safety.
Preclinical Testing
- Analysis of the distribution of the 99mTc-labeled compound in vivo to target specific organs or tissues.
- Studying the half-life, bioavailability, and metabolic properties of radiopharmaceutical in animal models.
99mTc Conjugation Service
Alfa Cytology employs 99mTc radioisotopes for labeling a diverse array of molecules, aiding in molecular imaging and biotracking studies.
Why Choose Us?
We offer services that range from molecular design to preclinical testing such that every stage of development is seamlessly integrated, ensuring efficiency, accuracy, and compliance with regulatory standards.
Experience in 99mTc Chemistry
Full-Service Development
State-of-the-Art Facilities
Application-Specific Tailored Solutions
Supported by an advanced research platform, an experienced R&D team, and close collaborations with leading academic institutions and industry partners, Alfa Cytology possesses strong technical expertise and innovative capabilities to offer comprehensive solutions in the development and production of 99mTc radiopharmaceuticals.Please do not hesitate to contact us for further information about Alfa Cytology's 99mTc radiopharmaceutical development services, or to discuss how we may support your unique radiopharmaceutical needs.
Reference
- Ilyushenkova, J., et al. (2020). Diagnostic Efficacy of Cardiac Scintigraphy with 99mTc-Pyrophosphate for Latent Myocardial Inflammation in Patients with Atrial Fibrillation. Cardiology research and practice. 5983751.
For research use only. Not intended for any clinical use.
Related Service
